View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 2, 2021updated 12 Jul 2022 11:22am

INOVIO reports positive data from HPV immunotherapy trial

INOVIO has reported that Phase III REVEAL 1 trial of DNA medicine, VGX-3100, to treat HPV-16/18-associated cervical high-grade squamous intraepithelial lesions (HSIL), met the primary and secondary endpoints in all evaluable subjects.

INOVIO has reported that Phase III REVEAL 1 trial of DNA medicine, VGX-3100, to treat HPV-16/18-associated cervical high-grade squamous intraepithelial lesions (HSIL), met the primary and secondary endpoints in all evaluable subjects.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

A pre-cancerous condition of the cervix, Cervical HSIL directly precedes invasive cervical cancer development.

This trial is one among the two ongoing pivotal, randomised, double-blind, multi-centre, placebo-controlled Phase III trials (REVEAL 1 and REVEAL 2).

It is analysing the safety, tolerability and efficacy of VGX-3100 for treating HPV-16/18-associated cervical HSIL using the CELLECTRA 5PSP device.

The REVEAL 1 trial enrolled 201 adult women with histologically confirmed cervical HSIL linked to HPV-16 and/or HPV-18, but who were otherwise healthy. They were randomised into a 2:1 ration to receive either VGX-3100 or placebo at zero, four, and 12 weeks.

At week 36, 23.7% of subjects in the treatment arm achieved statistically significant histopathological regression of HSIL combined with virologic clearance of HPV-16 and/or HPV-18 versus 11.3% in the placebo arm, thereby meeting the primary endpoint.

The trial also met all secondary efficacy endpoints: regression of cervical HSIL to normal tissue combined with HPV-16/18 viral clearance, regression of cervical HSIL alone, regression of cervical HSIL to normal tissue, and HPV-16/18 viral clearance alone.

Treatment-related serious adverse events were not observed in the trial.

INOVIO president and CEO Dr J Joseph Kim said: “INOVIO is very proud to advance VGX-3100 as the first DNA medicine to achieve efficacy endpoints in a Phase III clinical trial in all evaluable subjects.

“We expect VGX-3100, if approved, to be an important therapeutic option for those impacted by HPV-16-/18-related disease.

“The REVEAL 1 efficacy and safety data also represent an important proof-of-platform for INOVIO’s DNA medicines.”

The company will continue to follow up with the trial participants for safety and durability of response for 18 months following the last administration.

Along with Qiagen, INOVIO is working on developing a pre-treatment RNA-based biomarker blood test to detect women likely to respond to VGX-3100.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena